Literature DB >> 23990519

GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance.

Niina Matikainen1, Leonie H Bogl, Antti Hakkarainen, Jesper Lundbom, Nina Lundbom, Jaakko Kaprio, Aila Rissanen, Jens J Holst, Kirsi H Pietiläinen.   

Abstract

OBJECTIVE Impaired incretin response represents an early and uniform defect in type 2 diabetes, but the contributions of genes and the environment are poorly characterized. RESEARCH DESIGN AND METHODS We studied 35 monozygotic (MZ) and 75 dizygotic (DZ) twin pairs (discordant and concordant for obesity) to determine the heritability of glucagon-like peptide 1 (GLP-1) responses to an oral glucose tolerance test (OGTT) and the influence of acquired obesity to GLP-1, glucose-dependent insulinotropic peptide (GIP), and peptide YY (PYY) during OGTT or meal test. RESULTS The heritability of GLP-1 area under the curve was 67% (95% CI 45-80). Cotwins from weight-concordant MZ and DZ pairs and weight-discordant MZ pairs but concordant for liver fat content demonstrated similar glucose, insulin, and incretin profiles after the OGTT and meal tests. In contrast, higher insulin responses and blunted 60-min GLP-1 responses during the OGTT were observed in the heavier as compared with leaner MZ cotwins discordant for BMI, liver fat, and insulin sensitivity. Blunted GLP-1 response to OGTT was observed in heavier as compared with leaner DZ cotwins discordant for obesity and insulin sensitivity. CONCLUSIONS Whereas the GLP-1 response to the OGTT is heritable, an acquired unhealthy pattern of obesity characterized by liver fat accumulation and insulin resistance is closely related to impaired GLP-1 response in young adults.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23990519     DOI: 10.2337/dc13-1283

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  15 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release.

Authors:  José de Jesús Garduno-Garcia; Amalia Gastaldelli; Ralph A DeFronzo; Raweewan Lertwattanarak; Jens J Holst; Nicolas Musi
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

3.  Genetic determinants of circulating GIP and GLP-1 concentrations.

Authors:  Peter Almgren; Andreas Lindqvist; Ulrika Krus; Liisa Hakaste; Emilia Ottosson-Laakso; Olof Asplund; Emily Sonestedt; Rashmi B Prasad; Esa Laurila; Marju Orho-Melander; Olle Melander; Tiinamaija Tuomi; Jens Juul Holst; Peter M Nilsson; Nils Wierup; Leif Groop; Emma Ahlqvist
Journal:  JCI Insight       Date:  2017-11-02

Review 4.  Metabolically healthy and unhealthy obese--the 2013 Stock Conference report.

Authors:  D Samocha-Bonet; V D Dixit; C R Kahn; R L Leibel; X Lin; M Nieuwdorp; K H Pietiläinen; R Rabasa-Lhoret; M Roden; P E Scherer; S Klein; E Ravussin
Journal:  Obes Rev       Date:  2014-07-25       Impact factor: 9.213

5.  Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.

Authors:  Niina Matikainen; Elias Björnson; Sanni Söderlund; Christofer Borén; Björn Eliasson; Kirsi H Pietiläinen; Leonie H Bogl; Antti Hakkarainen; Nina Lundbom; Angela Rivellese; Gabriele Riccardi; Jean-Pierre Després; Natalie Alméras; Jens Juul Holst; Carolyn F Deacon; Jan Borén; Marja-Riitta Taskinen
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

6.  GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals.

Authors:  Martin Larsson; Cesare Patrone; Mia von Euler; Jens J Holst; David Nathanson
Journal:  Cardiovasc Diabetol       Date:  2019-07-15       Impact factor: 9.951

7.  Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.

Authors:  John M Dennis; Beverley M Shields; Anita V Hill; Bridget A Knight; Timothy J McDonald; Lauren R Rodgers; Michael N Weedon; William E Henley; Naveed Sattar; Rury R Holman; Ewan R Pearson; Andrew T Hattersley; Angus G Jones
Journal:  Diabetes Care       Date:  2018-01-31       Impact factor: 19.112

8.  Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study.

Authors:  Niina Matikainen; Sanni Söderlund; Elias Björnson; Kirsi Pietiläinen; Antti Hakkarainen; Nina Lundbom; Marja-Riitta Taskinen; Jan Borén
Journal:  Diabetes Obes Metab       Date:  2018-09-04       Impact factor: 6.577

Review 9.  What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?

Authors:  Rune E Kuhre; Carolyn F Deacon; Jens J Holst; Natalia Petersen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

10.  The Postprandial Glycaemic and Hormonal Responses Following the Ingestion of a Novel, Ready-to-Drink Shot Containing a Low Dose of Whey Protein in Centrally Obese and Lean Adult Males: A Randomised Controlled Trial.

Authors:  Kieran Smith; Guy S Taylor; Dean M Allerton; Lise Hoej Brunsgaard; Kelly A Bowden Davies; Emma J Stevenson; Daniel J West
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.